Advertisement

Klinik — orale Medikation

  • W. Kuhn
  • T. Müller

Zusammenfassung

Da die Ursache des degenerativen Prozesses beim M. Parkinson noch unbekannt ist, ist eine kausale Therapie nicht mÖglich. Primäres Ziel der symptomatisch orientierten medikamentÖsen Therapie ist somit der Ausgleich des Striatalen Dopamindefizits entweder durch Substitution mit L-Dopa oder durch Verbesserung der dopaminergen Transmission. Von besonderer Bedeutung ist dabei die Stimulation postsynaptischer D1- und D2-Rezeptoren durch Dopaminagonisten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlskog JE, Muenter MD (1988a) Pergolide: long-term use in Parkinson’s disease. Mayo Clin Proc 63: 979–987PubMedCrossRefGoogle Scholar
  2. Ahlskog JE, Muenter MD (1988b) Treatment of Parkinson’s disease with pergolide: a double-blind study. Mayo Clin Proc 63: 969–978PubMedCrossRefGoogle Scholar
  3. Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K (1994) Fluctuating Parkinson’s disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 51: 1236–1241PubMedCrossRefGoogle Scholar
  4. Bergamasco B, Benna P, Scarzella L (1990) Long-term bromocriptine treatment of de novo patients with Parkinson’s disease. A seven-year follow-up. Acta Neurol Scand 81: 383–387PubMedCrossRefGoogle Scholar
  5. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B (1995) A combined levodopa test as a useful method evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 10: 668–671PubMedCrossRefGoogle Scholar
  6. Calne DB, Teychenne PF, Claveria LE et al. (1974) Bromocriptine in parkinsonism. Br Med J 4: 442–444PubMedCrossRefGoogle Scholar
  7. Calne DB, Teychenne PF, Leigh PN (1974) Treatment of Parkinsonism with bromocriptine. Lancet ii: 1355–1358CrossRefGoogle Scholar
  8. Calne DB, Plotkin CH, Williams AC, Nutt JG, Neophytides A, Teychenne PF (1978) Longterm treatment of Parkinsonism with bromocriptine. Lancet i: 735–737CrossRefGoogle Scholar
  9. Canonico PL (1993) Relative bioequivalence of three oral forms of daverium: capsules, tablets, oral drops. Study with a single dose of 20 mg in male and female volunteers (unpublished)Google Scholar
  10. Dupont E, Boas J, Mikkelsen B, Wermuth L, Worm-Petersen J (1996) The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine. Eur J Neurol 3[Suppl 1]: 9–12Google Scholar
  11. Emskotter T, Lachenmayer L, Heidenreich C (1989) The problems of L-dopa therapy in the course of Parkinson syndrome. Fortschr Neurol Psychiatr 57: 192–197PubMedCrossRefGoogle Scholar
  12. Factor SA, Weiner WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 8: 257–262PubMedCrossRefGoogle Scholar
  13. Fischer PA, Przuntek H, Majer M, Welzel D (1984) Combined treatment of the early stages of Parkinson’s syndrome with bromocriptine and levodopa. The results of a multicenter study. Dtsch Med Wochenschr 109: 1279–1283PubMedCrossRefGoogle Scholar
  14. Grimes JD, Kind DB, Kofman OS, Molina-Negro P, Wilson AF, Bouchard S (1984) Bromocriptine in the management of end of dose deterioration in Parkinson’s disease. Can J Neurol Sci 11: 452–456PubMedGoogle Scholar
  15. Guttman M, Frcpc, AND the International Pramipexole-Bromocriptine Study Group (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 49: 1060–1065PubMedCrossRefGoogle Scholar
  16. Heinz A, Suchy I, Klewin I, Kuhn W, Klotz P, Przuntek H (1992) Long-term observation of chronic subcutaneous administration of lisu-ride in the treatment of motor fluctuations in Parkinson’s disease. J Neural Transm [PD-Sect] 4: 291–301CrossRefGoogle Scholar
  17. Hely MA, Morris JGL, Reid WGJ, O’Sullivan DJ, Williamson PM (1994) The Sydney Multicentre Study of Parkinson’s disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57: 903–910PubMedCrossRefGoogle Scholar
  18. Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogenmaleate, an ergot derivative, in mice. Eur J Pharmacol 36: 373–383PubMedCrossRefGoogle Scholar
  19. Horowski R, Obeso JA (1990) Lisuride: a direct dopamine agonist in the treatment of Parkinson’s disease. In: Koller WC, Paulson G (eds) Therapy in Parkinson’s disease. Marcel Dekker, New York, pp 269–309Google Scholar
  20. Horstink MW, Berger HJ, van de Vlasakker CJ (1995) Cabergoline in Parkinson’s disease. Neurology 45: 1233–1234PubMedCrossRefGoogle Scholar
  21. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI et al. (1996) Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 46: 1062–1065PubMedCrossRefGoogle Scholar
  22. Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine — a review. Psychopharmacology Berl 95: 433–446PubMedCrossRefGoogle Scholar
  23. Jörg J, Schneider I (1988) Clinical aspects and pathogenesis of the „on-off“ phenomenon in Parkinson syndrome. Fortschr Neurol Psychiatr 56: 22–34PubMedCrossRefGoogle Scholar
  24. Korcyn AD, Brooks D, Brunt ER, Poewe WH, Rascol O et al. (1998) Ropinirol versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. Mov Disord 13: 46–51CrossRefGoogle Scholar
  25. Lees AJ (1994) Levodopa substitution: the gold standard. Clin Neuropharmacol 17: 1–6CrossRefGoogle Scholar
  26. Lees AJ, Stern GM (1983) Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 1020–1023CrossRefGoogle Scholar
  27. Lera G, Vaamonde, J Muruzabal, J, Obeso JA (1990) Cabergoline: a long-acting dopamine agonist in Parkinson’s disease. Ann Neurol 28: 593–594PubMedCrossRefGoogle Scholar
  28. Lera G, Vaamonde J, Rodriguez M, Obeso JA (1993) Cabergoline in Parkinson’s disease: long-term follow-up. Neurology 43: 2587–2590PubMedCrossRefGoogle Scholar
  29. Le Witt PA, Ward CD, Larsen TA, et al. (1983) Comparison of pergolide and bromocriptine in parkinsonism. Neurology 33: 1009–1014CrossRefGoogle Scholar
  30. Lieberman A, Gopinathan G, Neophytides A, Goldstein M (1986) Management of levodopa failure: the use of dopamine agonists. Clin Neuropharmacol 9[Suppl 1]: 9–21Google Scholar
  31. Lieberman A, Gopinathan G, Neophytides A, Nelson J, Goldstein M (1990) Dopamine agonists in Parkinson’s disease. In: Stern G (ed) Parkinson’s disease. Chapman Hall, London, pp 509–557Google Scholar
  32. Lieberman A, Ranhasky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49: 162–168PubMedCrossRefGoogle Scholar
  33. Luquin MR, Obeso JA, Martinez Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1987) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45: 561–568PubMedGoogle Scholar
  34. Madeja UD (1992) The dopamine agonist, lisuride, in the therapy of Parkinson disease. Acta Histochem [Suppl] 42: 25–31Google Scholar
  35. Marsden CD (1990) Parkinson’s disease. Lancet 335: 948–952PubMedCrossRefGoogle Scholar
  36. Mear J, Barroche G, de Smet Y, et al. (1984) Pergolide in the treatment of Parkinson’s disease. Neurology 34: 983–986PubMedCrossRefGoogle Scholar
  37. Meneghetti G, Bracco F, Giometto B, Ferla S, Schergna E (1986) Therapeutic effect of lisuride in advanced Parkinson’s disease. Eur Neurol 25: 74–80PubMedCrossRefGoogle Scholar
  38. Mierau J, Schingnitz G (1992) Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215: 161–170PubMedCrossRefGoogle Scholar
  39. Mizuno Y, Kondo T, Narabayashi H (1995) Pergolide in the treatment of Parkinson’s disease. Neurology 45[Suppl 3]: S13–S21PubMedCrossRefGoogle Scholar
  40. Montastruc JL, Rascol O, Rascol A (1988) Bromocriptine versus levodopa in the early treatment of Parkinson’s disease. First results after 2 years. Therapie 43: 461–463PubMedGoogle Scholar
  41. Montastruc JL, Rascol O, Rascol A (1989) A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 52: 773–775PubMedCrossRefGoogle Scholar
  42. Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 57: 1034–1038PubMedCrossRefGoogle Scholar
  43. Obeso JA, Grandas F, Herrero MT, Horowski R (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson’s disease. Eur J Neurosci 6: 889–897PubMedCrossRefGoogle Scholar
  44. Ogawa N, Kanazawa I, Kowa H, Kuno S, Mizuno Y, Tashiro K, Yanagisawa N (1997) Nationwide multicenter prospective study on the long-term effects of bromocriptine in Parkinson’s disease. Eur Neurol 38[Suppl 2]: 37–49PubMedCrossRefGoogle Scholar
  45. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J et al. (1994) A multi-center double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 9: 40–47PubMedCrossRefGoogle Scholar
  46. Olanow CW, Hauser RA, Ganger L et al. (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777PubMedCrossRefGoogle Scholar
  47. Pahwa R, Koller WC (1995) Dopamine agonists in the treatment of Parkinson’s disease. Cleve Clin J Med 62: 212–217PubMedGoogle Scholar
  48. Pezzoli G, Martignoni E, Pacchetti C, Angeleri V, Lamberti P, Muratorio A, Bonuccelli U, de Mari M, Foschi N, Cossutta E et al. (1995) A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease. Neurology 45: S22–22S27CrossRefGoogle Scholar
  49. Poewe W (1995) Pergolid. Akt Neurol 22: 71–74CrossRefGoogle Scholar
  50. Przuntek H, Welzel D, Blumner E, Danielczyk W, Letzel H, Kaiser HJ, Kraus PH, Riederer P, Schwarzmann D, Wolf H et al. (1992a) Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: pra-do-study discontinued. Eur J Clin Pharmacol 43: 357–363PubMedCrossRefGoogle Scholar
  51. Przuntek H, Welzel D, Schwarzmann D, Letzel H, Kraus PH (1992b) Primary combination therapy of early Parkinson’s disease. A long-term comparison between the combined regimen bromo-criptine/levodopa and levodopa monotherapy — first interim report. Eur Neurol 32[Suppl 1]: 36–45PubMedCrossRefGoogle Scholar
  52. Przuntek H, Welzel D, Gerlach M, Blummer E, Danielczyk W, Kaiser HJ et al. (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699–715PubMedCrossRefGoogle Scholar
  53. Rascol A, Montastruc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson’s disease? Can J Neurol Sci 11: 229–232PubMedGoogle Scholar
  54. Rascol OJ (1994) Antiparkinsonian efficacy of ropirinole vs placebo as early therapy in Parkinson’s disease. New Trends Clin Pharmacol 8: 279 (Abstract)Google Scholar
  55. Rascol O, Brooks D, Brunt ER, Korczyn AD, Poewe WH et al. (1998) Ropinirol in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 13(1): 39–45PubMedCrossRefGoogle Scholar
  56. Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, Mcdonald R, Wutke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431–442Google Scholar
  57. Rinne UK (1987a) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–828PubMedCrossRefGoogle Scholar
  58. Rinne UK (1987b) R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 149–155Google Scholar
  59. Rinne UK (1987c) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–523PubMedGoogle Scholar
  60. Rinne UK (1988) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–523Google Scholar
  61. Rinne UK (1989a) Early dopamine agonist therapy in Parkinson’s disease. Mov Disord 4[Suppl 1]: S86–S94PubMedCrossRefGoogle Scholar
  62. Rinne UK (1989b) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339PubMedCrossRefGoogle Scholar
  63. Rinne UK (1999) Kombinationstherapie mit Lisurid und L-Dopa in den FrÜhstadien der Parkinson-Krankheit verringert und verzÖgert die Entwicklung motorischer Fluktuationen. Nervenarzt 70[Suppl 1]: S19–S25PubMedCrossRefGoogle Scholar
  64. Rinne UK, Bracco F, Chonza C, Dupont E, Gershamik O et al. (1997) Cabergoline in the treatment of early Parkinson’s disease. Neurology 48: 363–368PubMedCrossRefGoogle Scholar
  65. Schneider E (1995) Alpha-Dihydoergocryptin — Pharmakologie und klinische Effekte. In: Deuschl G (Hrsg) Alpha-dihydroergocryptin — ein neuer Dopamin-Agonist. Thieme, Stuttgart New York, S 7–42Google Scholar
  66. Schneider E, Fischer PA, Jacobi R, Kolb R (1981) Mortalität beim Parkinson-Syndrom und ihre Beeinflussung durch L-Dopa. Fortschr Neurol Psychiatr 49: 187–194PubMedCrossRefGoogle Scholar
  67. Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogenous psychoses in Parkinson syndrome. Frequency and causal conditions. Fortschr Neurol Psychiatr 52: 207–214PubMedCrossRefGoogle Scholar
  68. Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL et al. (1998) Ropinirole for the treatment of early Parkinson’s disease. Arch Neurol 55: 1211–1216PubMedCrossRefGoogle Scholar
  69. Shannon KM, Benett JP, Friedman JH, for the Pramipexole Study Group (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 49: 724–728PubMedCrossRefGoogle Scholar
  70. Stammler A, Vielhaber K (1972) Die Behandlung des Parkinsonsyndroms mit Dopa in Kombination mit einem Decarboxylasehemmer. Fortschr Neurol Psychiatr 40: 564–568Google Scholar
  71. Steiger MJ, El-Debus T, Andersson T, Findley LJ, Marsden CD (1996) Double-blind study of the activity and tolerability of cabergolin versus placebo in parkinsonians with motor fluctuations. J Neurol 243: 68–72PubMedCrossRefGoogle Scholar
  72. Suchy I, Horowski R (1984) Use of ergot derivative lisuride in Parkinson’s disease. Adv Neurol 40: 515–521PubMedGoogle Scholar
  73. Walters JW (1987) D1-dopamine receptor activation required for postsynaptic expression on D2-agonists effects. Science 236: 719–722PubMedCrossRefGoogle Scholar
  74. Watts RL (1997) The role of dopamine agonists in early Parkinson’s disease. Neurology 49[Suppl 1]: 34–48CrossRefGoogle Scholar
  75. Weiner WJ, Factor SA, Sanchez Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease [see comments]. Neurology 43: 21–27PubMedCrossRefGoogle Scholar
  76. Wolters E, Tissingh G, Bergmans PLM, Kuiper MA (1995) Dopamine agonists in Parkinson’s disease. Neurology 45[Suppl 3]: S28–S34PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • W. Kuhn
  • T. Müller

There are no affiliations available

Personalised recommendations